Bleeding with anticoagulant treatments

G. Palareti

doi:10.5482/ha-1151

Hämostaseologie, Table of Contents

Hamostaseologie 2011; 31(04): 237-242
DOI: 10.5482/ha-1151

Review

Schattauer GmbH

Bleeding with anticoagulant treatments

Blutungen unter Antikoagulanzientherapie

G. Palareti

¹Dept. Angiology and Blood Coagulation, University Hospital S. Orsola-Malpighi, Bologna, Italy

› Author Affiliations

Abstract

Summary

Anticoagulation with vitamin K antagonists (VKAs) is effective in the prevention and treatment of thrombotic complications in many clinical conditions, including atrial fibrillation (that represents today the most frequent indication for anticoagulant treatment), venous thromboembolism, acute coronary syndromes and after invasive cardiac procedures. Bleeding is the most important complication of VKAs and a major concern for both physicians and patients, limiting a more widespread prescription of the treatment. As a result, a non negligible proportion of all the subjects who would have a clear clinical indication for anticoagulation do not receive an effective treatment.

This review analyses the treatment- and person-associated risk factors for bleeding during VKAs. New oral anticoagulant drugs seems to overcome at least some of the limitations of VKAs. Potentially, they can allow a less demanding and more stable anticoagulant treatment, with less side-effects allowing that more patients can receive an appropriate anticoagulant treatment. Based on the so far available phase III clinical studies, it is possible to assume that these new drugs are associated with a risk of bleeding, that is probably related to the intensity of treatment.

Zusammenfassung

Die Antikoagulation mit Vitamin-K-Antagonisten (VKA) ist in der Prävention und Therapie von thrombotischen Komplikationen bei vielen Krankheitsbildern wirksam: u. a. bei Vorhofflimmern (zurzeit die häufigste Indikation für eine Antikoagulanzientherapie), venöse Thromboembolien, akutes Koronarsyndrom und nach invasiven kardialen Interventionen. Blutungen sind die wichtigste Komplikation der VKA-Gabe und die größte Sorge von Ärzten und Patienten, was die breitere Ver ordnung von VKA einschränkt. Daraus folgt, dass ein erheblicher Teil der Patienten, bei denen eine klare Indikation für eine Antikoagulation bestehen würde, keine wirksame Therapie erhält.

In dieser Übersicht analysieren wir die behandlungs- und patientenbezogenen Risikofaktoren für Blutungen unter VKA. Mit neuen oralen Antikoagulanzien scheinen einige der Einschränkungen der VKA überwunden zu sein. Möglicherweise gestatten sie eine weniger aufwändige und stabilere Antikoagulanzientherapie mit weniger unerwünschten Arzneimittelwirkungen, so dass mehr Patienten eine adäquate gerinnungshemmende Therapie erhalten können. Den vorliegenden klinischen Phase-III-Studien zufolge ist davon auszugehen, dass auch die neuen Antithrombotika mit einem Blutungsrisiko verbunden sind, das wahrscheinlich von der Intensität der Behandlung abhängig ist.

Keywords

Anticoagulation - vitamin K antagonists - bleeding - new oral anticoagulants

Schlüsselwörter

Antikoagulation - Vitamin-K-Antagonisten - Blutung - neue orale Antikoagulanzien

Full Text

References

References
1 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
2 Levi M, Hovingh GK, Cannegieter SC. et al. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008; 111: 4471-4476.
3 Fanikos J, GrassoCorrenti N, Shah R. et al. Major bleeding complications in a specialized anticoagulation service. Am J Cardiol 2005; 96: 595-598.
4 Linkins LA, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a metaanalysis. Ann Intern Med 2003; 139: 893-900.
5 Vecsler M, Loebstein R, Almog S. et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 2006; 95: 205-211.
6 Joffe HV, Xu R, Johnson FB. et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004; 91: 1123-1128.
7 Rieder MJ, Reiner AP, Gage BF. et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
8 Meckley LM, Wittkowsky AK, Rieder MJ. et al. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost 2008; 100: 229-239.
9 Aithal GP, Day CP, Kesteven PJL. et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-719.
10 Schwarz UI, Ritchie MD, Bradford Y. et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008; 358: 999-1008.
11 Sconce EA, Khan TI, Wynne HA. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106: 2329-2333.
12 Oldenburg J, Quenzel EM, Harbrecht U. et al. Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. Br J Haematol 1997; 98: 240-244.
13 Palareti G, Leali N, Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception- cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-428.
14 Fihn SD, Callahan CM, Martin DC. et al. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med 1996; 124: 970-979.
15 Steffensen FH, Kristensen K, Ejlersen E. et al. Major haemorrhagic complications during oral anticoagulant therapy in a danish population-based cohort. J Intern Med 1997; 242: 497-503.
16 Wickramasinghe LSP, Basu SK, Bansal SK. Longterm oral anticoagulant therapy in elderly patients. Age Ageing 1988; 17: 388-396.
17 Redwood M, Taylor C, Bain BJ. et al. The association of age with dosage requirement for warfarin. Age Ageing 1991; 20: 217-220.
18 Keeling D. Duration of anticoagulation: decision making based on absolute risk. Blood Rev 2006; 20: 173-178.
19 Hylek EM, Singer DE. Risk factors far intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
20 Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage – facts and hypotheses. Stroke 1995; 26: 1471-1477.
21 Palareti G, Hirsh J, Legnani C. et al. Oral anticoagulation treatment in the elderly – A nested, prospective, case-control study. Arch Intern Med 2000; 160: 470-478.
22 Fang MC, Chang YC, Hylek EM. et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004; 141: 745-752.
23 Shorr RI, Ray WA, Daugherty JR. et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993; 153: 1665-1670.
24 Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastro enterol 1997; 92: 419-424.
25 Smith EE, Rosand J, Knudsen KA. et al. Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology 2002; 59: 193-197.
26 Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001; 57: 1993-1999.
27 Dahl T, Abildgaard U, Sandset PM. Long-term anticoagulant therapy in cerebrovascular disease: does bleeding outweigh the benefit?. J Intern Med 1995; 237: 323-329.
28 Petty GW, Brown RD, Whisnant JP. et al. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention – A population-based study. Ann Intern Med 1999; 130: 14-22.
29 Algra A. Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. Stroke 2003; 34: E45-E6.
30 Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-99.
31 Kuijer PMM, Hutten BA, Prins MH. et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-460.
32 Palareti G, Legnani C, Lee A. et al. A comparison of the safety and efficacy of oral antiocoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000; 84: 805-810.
33 Hutten BA, Prins MH, Gent M. et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
34 Prandoni P, Lensing AWA, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-3488.
35 Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: A meta-analysis and hypothesis. Cerebrovasc Dis 1999; 09: 215-217.
36 Rothberg MB, Celestin C, Fiore LD. et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: Meta-analysis with estimates of risk and benefit. Ann Intern Med 2005; 143: 241-250.
37 Sorensen R, Hansen ML, Abildstrom SZ. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009; 374: 1967-1974.
38 Mellemkjaer L, Blot WJ, Sorensen HT. et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173-181.
39 Landefeld CS, Rosenblatt MW, Goldman L. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med 1989; 87: 153-159.
40 Schulman S, Beyth RJ, Kearon C. et al. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 257S-298S.
41 Hylek EM, Go AS, Chang YC. et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
42 Hylek EM, EvansMolina C, Shea C. et al. Major Hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-2696.
43 Ansell J, Hirsh J, Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133: 160S-198S.
44 Fihn SD, Gadisseur AA, Pasterkamp E. et al. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003; 90: 260-266.
45 Palareti G, Legnani C, Guazzaloca G. et al. Risks factors for highly unstable response to oral anticoagulation: a case-control study. Br J Haematol 2005; 129: 72-78.
46 Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998; 158: 1641-1647.
47 Heneghan C, AlonsoCoello P, Garcia JMAlamino. et al. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 2006; 367: 404-411.
48 Poller L, Keown M, Ibrahim S. et al. An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. J Thromb Haemost 2008; 06: 935-943.
49 Lee AYY, Levine MN, Baker RI. et al. Low-molecularweight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146-153.
50 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
51 Schulman S, Kearon C, Kakkar AK. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352.
52 Bauersachs R, Berkowitz SD, Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510.
53 Mismetti P, Quenet S, Levine M. et al. Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism – An individual patient data meta-analysis. Chest 2005; 128: 2203-2210.
54 Petersen JL, Mahaffey KW, Hasselblad V. et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes – A systematic overview. JAMA Journal of the American Medical Association 2004; 292: 89-96.
55 FRISC Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999; 354: 708-715.
56 Simonneau G, Sors H, Charbonnier B. et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.
57 Buller HR, Cohen AT, Davidson B. et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
58 Buller HR, Cohen AT, Davidson B. et al. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med 2007; 357: 1105-1112.
59 Joyner CD, Peters RJ, Afzal R. et al. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. Am Heart J 2009; 157: 502-508.
60 Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thromboembolism. Eur Heart J. 2011 doi:10.1093/eurheartj/ehr052.
61 Connolly SJ, Eikelboom J, Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817.